Previously, we had reported that NEK2 overexpression induces drug resistance, proliferation and CIN in cancer cells.[11] In this study, we found that patients with combined defects of NEK2 activation and p53 inactivation suffer from poor survival and that collaboration between NEK2 and TP53 defects augments MM cell growth and drug resistance in vitro and in vivo. The gene discussed is TP53; the disease is Miyoshi myopathy.